Compare WHG & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHG | CNTB |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 135.7M |
| IPO Year | 2002 | 2020 |
| Metric | WHG | CNTB |
|---|---|---|
| Price | $17.11 | $2.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 9.4K | ★ 187.2K |
| Earning Date | 04-30-2026 | 08-13-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | ★ 203.85 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $97,762,000.00 | $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $191.89 | ★ N/A |
| Revenue Growth | ★ 3.21 | N/A |
| 52 Week Low | $14.70 | $0.77 |
| 52 Week High | $18.99 | $3.82 |
| Indicator | WHG | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 41.11 |
| Support Level | $16.82 | $2.03 |
| Resistance Level | $17.22 | $2.68 |
| Average True Range (ATR) | 0.56 | 0.19 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 72.70 | 11.48 |
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its Advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States, and also has its presence in Canada.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.